TNFRSF19 and central nervous system cancer: In the TCGA cohort, there was a significant increase in the fraction of genome alteration, tumor mutational burden, and copy number alteration fraction in gliomas exhibiting high expression of TNFRSF19 compared to those with low expression of TNFRSF19 (P < 0.05, as shown in Fig. 6I), indicating that gliomas with high TNFRSF19 expression display heightened immunogenicity.